A randomized placebo-controlled clinical trial for pharmacological activation of BCAA catabolism in patients with type 2 diabetes

Elevations in plasma branched-chain amino acid (BCAA) levels associate with insulin resistance and type 2 diabetes (T2D). Pre-clinical models suggest that lowering BCAA levels improve glucose tolerance, but data in humans are lacking. Here, we used sodium phenylbutyrate (NaPB), an accelerator of BCA...

Descripción completa

Detalles Bibliográficos
Autores principales: Vanweert, Froukje, Neinast, Michael, Tapia, Edmundo Erazo, van de Weijer, Tineke, Hoeks, Joris, Schrauwen-Hinderling, Vera B., Blair, Megan C., Bornstein, Marc R., Hesselink, Matthijs K. C., Schrauwen, Patrick, Arany, Zoltan, Phielix, Esther
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9206682/
https://www.ncbi.nlm.nih.gov/pubmed/35717342
http://dx.doi.org/10.1038/s41467-022-31249-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9206682/
https://www.ncbi.nlm.nih.gov/pubmed/35717342
http://dx.doi.org/10.1038/s41467-022-31249-9

Ejemplares similares